Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 14, showing 10 Applications out of 133 total, starting on record 21, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

21.

ECCT/23/11/01   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. AHERO CLINICAL TRIALS UNIT (Kisumu county)
3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
 
20-02-2024 View

22.

ECCT/23/12/04   GBT021601 OLE
    An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertude\'s Children\'s Hospital (Nairobi City county)
2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county)
3. KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county)
4. KEMRI CRDR SIAYA (Siaya county)
 
17-03-2024 View

23.

ECCT/23/10/05   CAPTURE-2
    Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents with Plasmodium falciparum Malaria Infection.   
Principal Investigator(s)
1. Dr Lucas Otieno Tina Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute
 
16-02-2024 View

24.

ECCT/23/08/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Nduba Videlis
Site(s) in Kenya
1. Getrudes Children Hospital (Nairobi City county)
2. KEMRI/CRDR (Siaya county)
3. Kombewa CRC (Kisumu county)
4. Kondele Childrens Hospital (Kisumu county)
 
18-10-2023 View

25.

ECCT/23/10/01   CROSSWALK Chronic (C)
    A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Doreen Terry Karimi
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
10-01-2024 View

26.

ECCT/23/07/04   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Dr. Janet Oyieko
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county)
 
28-08-2023 View

27.

ECCT/23/07/01   POWWeR Health Study
    Single arm trial of menstrual cups among economically vulnerable women to reduce Bacterial vaginosis and STIs through reduced harmful sexual and menstrual practices (POWWeR Health Study): A Phase 2 Trial   
Principal Investigator(s)
1. Fredrick Otieno
2. Supriya Dinesh Mehta
Site(s) in Kenya
Nyanza Reproductive Health Society
 
20-12-2023 View

28.

ECCT/23/07/05   Sabin
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults    
Principal Investigator(s)
1. Prof. Videlis Nduba Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
11-09-2023 View

29.

ECCT/23/06/09   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Walter Otieno
2. Videlis Nduba
Site(s) in Kenya
1. Kombewa Clinical research Centre (Kisumu county)
2. KEMRI, Siaya Clinical Research Annex (Kisumu county)
 
19-07-2024 View

30.

ECCT/23/06/08   TSCV3000
    Age-descending, randomized, placebo-controlled Phase 2 trial in three sites in sub-Saharan Africa to assess the safety and immunogenicity of a parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) versus placebo   
Principal Investigator(s)
1. RICHARD ONYANDO OMORE
Site(s) in Kenya
1. SIAYA COUNTY REFERRAL HOSPITAL (Siaya county)
2. ST. ELIZABETH LWAK HOSPITAL (Siaya county)
 
25-09-2023 View